Literature DB >> 29554238

Prevalence and Correlates of Trichomonas vaginalis Infection Among Men and Women in the United States.

Eshan U Patel1, Charlotte A Gaydos2, Zoe R Packman1, Thomas C Quinn3, Aaron A R Tobian1.   

Abstract

Background: The epidemiology of Trichomonas vaginalis (TV) infection in the United States is poorly defined.
Methods: Males and females aged 18-59 years who participated in the 2013-2014 National Health and Nutrition Examination Survey and provided a urine specimen were tested for TV infection (n = 4057). Participants were also examined for Chlamydia trachomatis (CT) infection, genital human papillomavirus (HPV) infection, and herpes simplex virus type 2 serostatus. Weighted adjusted prevalence ratios (aPRs) were estimated by multivariable Poisson regression.
Results: TV infection prevalence was 0.5% and 1.8% among males and females, respectively. TV infection prevalence was 4.2% among black males, 8.9% among black females, and 0.03% and 0.8%, respectively, among males and females of other races/ethnicities. TV infection prevalence (aPR [95% confidence interval]) was positively associated with female sex (6.1 [3.3-11.3]), black race (vs other races/ethnicities; 7.9 [3.9-16.1]), older age (vs 18-24 years; 3.0 [1.2-7.1] for 25- to 39-year-olds and 3.5 [1.3-9.4] for 40- to 59-year-olds), having less than a high school education (vs completing high school or more; 2.0 [1.0-4.1]), being below the poverty level (vs at or above the poverty level; 4.0 [2.1-7.7]), and having ≥2 sexual partners in the past year (vs 0-1 sexual partners; 3.6 [2.0-6.6]). There were no TV and CT coinfections. Genital HPV detection was not independently associated with TV infection. Among persons aged 18-39 years, there was a significant racial disparity in all sexually transmitted infections examined, and this disparity was greatest for TV infection. Conclusions: There is a high and disproportionate burden of urinary TV infection in the adult civilian, noninstitutionalized black population in the United States that warrants intervention.

Entities:  

Mesh:

Year:  2018        PMID: 29554238      PMCID: PMC6031067          DOI: 10.1093/cid/ciy079

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  36 in total

Review 1.  Examining racial disparities in HIV: lessons from sexually transmitted infections research.

Authors:  Julie Kraut-Becher; Marlene Eisenberg; Chelsea Voytek; Tiffany Brown; David S Metzger; Sevgi Aral
Journal:  J Acquir Immune Defic Syndr       Date:  2008-03-01       Impact factor: 3.731

2.  Trichomonas vaginalis and Human Immunodeficiency Virus Coinfection Among Women Under Community Supervision: A Call for Expanded T. vaginalis Screening.

Authors:  Alissa Davis; Anindita Dasgupta; Dawn Goddard-Eckrich; Nabila El-Bassel
Journal:  Sex Transm Dis       Date:  2016-10       Impact factor: 2.830

Review 3.  Structural racism and health inequities in the USA: evidence and interventions.

Authors:  Zinzi D Bailey; Nancy Krieger; Madina Agénor; Jasmine Graves; Natalia Linos; Mary T Bassett
Journal:  Lancet       Date:  2017-04-08       Impact factor: 79.321

4.  Prevalence of Trichomonas vaginalis and coinfection with Chlamydia trachomatis and Neisseria gonorrhoeae in the United States as determined by the Aptima Trichomonas vaginalis nucleic acid amplification assay.

Authors:  C C Ginocchio; K Chapin; J S Smith; J Aslanzadeh; J Snook; C S Hill; C A Gaydos
Journal:  J Clin Microbiol       Date:  2012-05-23       Impact factor: 5.948

5.  Trichomonas vaginalis is associated with pelvic inflammatory disease in women infected with human immunodeficiency virus.

Authors:  Prashini Moodley; David Wilkinson; Cathy Connolly; Jack Moodley; A Willem Sturm
Journal:  Clin Infect Dis       Date:  2002-01-07       Impact factor: 9.079

6.  Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States.

Authors:  Fujie Xu; Maya R Sternberg; Benny J Kottiri; Geraldine M McQuillan; Francis K Lee; Andre J Nahmias; Stuart M Berman; Lauri E Markowitz
Journal:  JAMA       Date:  2006-08-23       Impact factor: 56.272

7.  Prevalence and correlates of Trichomonas vaginalis infection among female US federal prison inmates.

Authors:  Siobhan Sutcliffe; Sara B Newman; Andrew Hardick; Charlotte A Gaydos
Journal:  Sex Transm Dis       Date:  2010-09       Impact factor: 2.830

8.  The prevalence of Trichomonas vaginalis infection among reproductive-age women in the United States, 2001-2004.

Authors:  Madeline Sutton; Maya Sternberg; Emilia H Koumans; Geraldine McQuillan; Stuart Berman; Lauri Markowitz
Journal:  Clin Infect Dis       Date:  2007-10-15       Impact factor: 9.079

9.  Correlates of Trichomonas vaginalis Among Middle Age and Older Adults Who Use Drugs.

Authors:  Lauren E Hearn; Nicole Ennis Whitehead; Eugene M Dunne; William W Latimer
Journal:  Subst Use Misuse       Date:  2015-11-19       Impact factor: 2.164

10.  Trichomonas vaginalis infection is uncommon in the British general population: implications for clinical testing and public health screening.

Authors:  Nigel Field; Soazig Clifton; Sarah Alexander; Catherine A Ison; Rumena Khanom; Pamela Saunders; Gwenda Hughes; Laura Heath; Simon Beddows; Catherine H Mercer; Clare Tanton; Anne M Johnson; Pam Sonnenberg
Journal:  Sex Transm Infect       Date:  2016-09-29       Impact factor: 3.519

View more
  20 in total

Review 1.  Mycoplasma genitalium and Trichomonas vaginalis: addressing disparities and promoting public health control of two emerging sexually transmitted infections.

Authors:  Faye Korich; Neha G Reddy; Maria Trent
Journal:  Curr Opin Pediatr       Date:  2020-08       Impact factor: 2.856

2.  Trichomonas vaginalis Virus Among Women With Trichomoniasis and Associations With Demographics, Clinical Outcomes, and Metronidazole Resistance.

Authors:  Keonte J Graves; Arindam P Ghosh; Norine Schmidt; Peter Augostini; W Evan Secor; Jane R Schwebke; David H Martin; Patricia J Kissinger; Christina A Muzny
Journal:  Clin Infect Dis       Date:  2019-11-27       Impact factor: 9.079

3.  Specific Vaginal Bacteria Are Associated With an Increased Risk of Trichomonas vaginalis Acquisition in Women.

Authors:  Olamide D Jarrett; Sujatha Srinivasan; Barbra A Richardson; Tina Fiedler; Jacqueline M Wallis; John Kinuthia; Walter Jaoko; Kishor Mandaliya; David N Fredricks; R Scott McClelland
Journal:  J Infect Dis       Date:  2019-09-26       Impact factor: 5.226

4.  A systematic review of the literature on mechanisms of 5-nitroimidazole resistance in Trichomonas vaginalis.

Authors:  Keonte J Graves; Jan Novak; W Evan Secor; Patricia J Kissinger; Jane R Schwebke; Christina A Muzny
Journal:  Parasitology       Date:  2020-07-30       Impact factor: 3.234

5.  Is It Time to Stop Using Single-dose Oral Metronidazole for the Treatment of Trichomoniasis in Women?

Authors:  Christina A Muzny; Saralyn Richter; Patricia Kissinger
Journal:  Sex Transm Dis       Date:  2019-05       Impact factor: 2.830

6.  20S Proteasome as a Drug Target in Trichomonas vaginalis.

Authors:  Anthony J O'Donoghue; Betsaida Bibo-Verdugo; Yukiko Miyamoto; Steven C Wang; Justin Z Yang; Douglas E Zuill; Shoun Matsuka; Zhenze Jiang; Jehad Almaliti; Conor R Caffrey; William H Gerwick; Lars Eckmann
Journal:  Antimicrob Agents Chemother       Date:  2019-10-22       Impact factor: 5.191

7.  Prevalence of Trichomonas vaginalis Among Civilian, Noninstitutionalized Male and Female Population Aged 14 to 59 Years: United States, 2013 to 2016.

Authors:  Elaine W Flagg; Elissa Meites; Christi Phillips; John Papp; Elizabeth A Torrone
Journal:  Sex Transm Dis       Date:  2019-10       Impact factor: 2.830

Review 8.  Global prevalence of Trichomonas vaginalis among female sex workers: a systematic review and meta-analysis.

Authors:  Monirsadat Mirzadeh; Aida Vafae Eslahi; Meysam Olfatifar; Amir Abdoli; Elham Houshmand; Hamidreza Majidiani; Morteza Ghanbari Johkool; Setareh Askari; Sima Hashemipour; Milad Badri
Journal:  Parasitol Res       Date:  2021-06-25       Impact factor: 2.289

9.  Single-dose versus 7-day-dose metronidazole for the treatment of trichomoniasis in women: an open-label, randomised controlled trial.

Authors:  Patricia Kissinger; Christina A Muzny; Leandro A Mena; Rebecca A Lillis; Jane R Schwebke; Laura Beauchamps; Stephanie N Taylor; Norine Schmidt; Leann Myers; Peter Augostini; William E Secor; Martina Bradic; Jane M Carlton; David H Martin
Journal:  Lancet Infect Dis       Date:  2018-10-05       Impact factor: 25.071

10.  Performance evaluation and acceptability of point-of-care Trichomonas vaginalis testing in adult female emergency department patients.

Authors:  Yu-Hsiang Hsieh; Mitra K Lewis; Valentina G Viertel; Deanna Myer; Richard E Rothman; Charlotte A Gaydos
Journal:  Int J STD AIDS       Date:  2020-09-30       Impact factor: 1.359

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.